Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 4/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 2/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | VNN1 | O95497 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL764480 | 0.91 | BDKRB1 (0.53) | BDKRB1MAPK14CYP3A4SLC22A12VNN1 | |
| SCHEMBL765846 | 0.90 | BDKRB1 (0.49) | BDKRB1MAPK14CYP3A4VNN1CTSL | |
| SCHEMBL765805 | 0.90 | BDKRB1 (0.49) | BDKRB1MAPK14CYP3A4SLC22A12CTSL | |
| SCHEMBL765656 | 0.90 | BDKRB1 (0.49) | BDKRB1MAPK14CYP3A4VNN1CTSL | |
| SCHEMBL764449 | 0.90 | BDKRB1 (0.49) | BDKRB1MAPK14CYP3A4SLC22A12 | |
| SCHEMBL12239078 | 0.88 | BDKRB1 (0.54) | BDKRB1MAPK14CYP3A4LIPGMMP13 | |
| SCHEMBL765845 | 0.88 | MAPK14 (0.58) | BDKRB1MAPK14CYP3A4MMP13HTT | |
| SCHEMBL765145 | 0.87 | BDKRB1 (0.48) | BDKRB1MAPK14CYP3A4 | |
| SCHEMBL10121533 | 0.87 | BDKRB1 (0.53) | BDKRB1MAPK14CYP3A4LIPGMMP13 | |
| SCHEMBL12239087 | 0.87 | BDKRB1 (0.53) | BDKRB1MAPK14CYP3A4LIPGMMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916589-B2 | Bradykinin B1-antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-23 | — | — | US | disclosed |
| EP-2188254-B1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2012-03-21 | — | — | EP | disclosed |
| US-20110263626-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263626-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BDKRB1, BDKRB2, EDNRB | BDKRB1 1/4885MAPK14 1751/4885CYP3A4 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.